Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function

Journal of Clinical Pharmacology

Volumn 38, Issue 3, 1998, Pages 268-275

  Shaw, Leslie M ^a   Mick, Rosemarie ^a   Nowak, Irena ^a   Korecka, Magdalena ^a   Brayman, Kenneth L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; GRAFT FAILURE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE;

EID: 0031917826     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04424.x     Document Type: Article

References (19)

1. Allison AC, Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28.
2. Wu JC: Mycophenolate mofetil: molecular mechanisms of action. Perspect Drug Discovery Design 1994;2:185-204.
3. Bullingham RES, Nicholls A, Hale M: Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplantation Proc 1996;28:925-929.
4. Bullingham RES, Monroe S, Nicholls A, Hale M: Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315-324.
5. Parker G, Bullingham R, Kamm B, Hale M: Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996;36:332-344.
6. Bullingham R, Shah J, Goldblum R, Schiff M: Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis. Br J Clin Pharmacol 1996;41:513-516.
7. CellCept package insert. In, Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, 1997.
8. Nowak I, Shaw LM: Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit 1997;19:358-360.
9. Nowak I, Shaw LM: Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41:1011-1017.
10. Franklin TJ, Jacobs V, Jones G, Ple P, Bruneau P: Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res 1996;56:984-987.
11. Cecka JM, Terasaki PI: Clinical Transplants. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1996.
12. Tsina I, Chu F, Hama K, Kaloostain M, Tam YL, Tarnowski T, Wong B: Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in plasma. J Chromatogr 1996;675:119-129.
13. Neter J, Wasserman W, Kutner MH: Linear Statistical Methods. Homewood, IL: Irwin, 1985.
14. Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
15. Liang KY: Estimating function and approximate conditional likelihood. Biometrika 1987;4:695-702.
16. Tilney NL: The early course of a patient with a kidney transplant. In, Morris PJ (ed.): Kidney Transplantation: Principles and Practice. Philadelphia, PA: WB Saunders, 1988;263-283.
17. Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RWG, Najarian JS, Matas AJ: Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. Transplantation 1995;59:962-968.
18. Reidenberg MM, Drayer DE: Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984;9:18-26.
19. Halloran PF, Lui SL, Miller LW: Review of transplantation 1996. In, Cecka JM, Terasaki PI (eds.): Clinical Transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory, 1997;291-319.